Moderna initiates safety and immunogenicity study for RSV vaccines in infants
Moderna is conducting a study to evaluate the safety and immunogenicity of two mRNA vaccines targeting RSV and hMPV in infants.
Asset / Drug
Drug and asset intelligence for RSV with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Vaccine
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.